Coly Mycin M Injectable Product — Competitive Intelligence Brief

Coly Mycin M Injectable Product (Coly Mycin M Injectable Product) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Polymyxin antibiotic. Area: Infectious Disease.

phase 3 Polymyxin antibiotic Bacterial lipopolysaccharides and phospholipids Infectious Disease Small molecule

Target snapshot

Coly Mycin M Injectable Product (Coly Mycin M Injectable Product) — Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Colistin (polymyxin E) is a cyclic polypeptide antibiotic that disrupts bacterial cell membranes by binding to lipopolysaccharides and phospholipids, leading to cell lysis and death.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Coly Mycin M Injectable Product TARGET	Coly Mycin M Injectable Product	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	phase 3	Polymyxin antibiotic	Bacterial lipopolysaccharides and phospholipids
Polymyxin e	Polymyxin e	Mahmoud I Mostafa	marketed	Polymyxin antibiotic	Bacterial lipopolysaccharides and phospholipids
Standard Dose Colistin	Standard Dose Colistin	King Saud Medical City	marketed	Polymyxin antibiotic	Bacterial lipopolysaccharides and phospholipids
Ceftazidime-avibactam + Colistin/Polymyxin B	Ceftazidime-avibactam + Colistin/Polymyxin B	National University of Singapore	marketed	Beta-lactam/beta-lactamase inhibitor + polymyxin antibiotic combination	Bacterial peptidoglycan cross-linking enzymes (PBPs); beta-lactamases; bacterial cell membrane lipopolysaccharide and phospholipids
High Dose Colistin	High Dose Colistin	King Saud Medical City	marketed	Polymyxin antibiotic	Bacterial lipopolysaccharide (LPS) and outer membrane
Colistin/Polymyxin B + Sulbactam	Colistin/Polymyxin B + Sulbactam	National University of Singapore	marketed	Polymyxin antibiotic + β-lactamase inhibitor combination	Bacterial cell membrane (polymyxins); bacterial β-lactamases (sulbactam)
Colistimethate sodium for injection	Colistimethate sodium for injection	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	phase 3	Polymyxin antibiotic	Bacterial lipopolysaccharide and phospholipid membranes

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Polymyxin antibiotic class)

1. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 drugs in this class
2. King Saud Medical City · 2 drugs in this class
3. Hospitales Universitarios Virgen del Rocío · 1 drug in this class
4. Mahmoud I Mostafa · 1 drug in this class
5. Merck Sharp & Dohme LLC · 1 drug in this class
6. Vanderbilt University Medical Center · 1 drug in this class